Furthermore, PIGNON highlighted GO terms that were previously characterized in specific breast cancer subtypes, such as “epidermal growth factor receptor binding”, the “inactivation of MAPK activity” and “vesicle targeting” when analysing expression-weighted networks involving the HER2+ subtype [39, 46, 47]. This evidence concerns the gene ERBB2 and breast cancer.